Ovarian cancer (advanced) - pegylated liposomal doxorubicin hydrochloride (replaced by TA91)

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for the treatment of advanced ovarian cancer (review of TA28, TA45 and TA55 (for relapsed disease only))

Summary

This guidance is replaced by TA91 Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review).

Guidance documents

• No documents found

Implementing this guidance

• None available

Other information

• Background information

• This guidance is currently being reviewed